@MD) is injection of normal myoblasts into dystrophic muscles to induce formation of muscle fibers. To develop this therapy it is important to idennfy the injected myoblasts and the muscle fibers that they form in the host muscles.
Introduction
Transplantation of normal myoblasts into dystrophic muscles to form hybrid muscle cells (1-4) is a possible treatment for Duchenne muscular dystrophy (DMD). One of the problems associated with muscle cell hybridization in vivo is identification of transplanted myoblasts in the host muscle and the muscle fibers resulting from their fusion. Fluorescent latex microspheres (FLMs) have been reported to be phagocyzed by some living cells and to remain in the labeled cells (5-7). For example, FLM-labeled myoblasts were autotransplanted into an irradiated and ischemically damaged muscle to follow the formation of new muscle fibers (6) . In this study, FLMlabeled normal myoblasts were transplanted into the muscles of dystrophin-deficient mdx mice. The spread of injected normal myoblasts was revealed by the FLMs. In addition, FLMs were present in some of the dystrophin-positive muscle fibers in mdx muscle. These results indicate that labeling myoblasts with FLMs is a good way to follow the spread ofuansplanted cells and to idenufy regenerated muscle fibers created by fusion of FLM-labeled cells.
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Correspondence to: Jacques P. Tremblay, Laboratoire de Neurobiologie. H8pital de 1' Enfant-Jesus, 1401, 18e Rue, Quebec, Canada GlJ 124. positive fibers in each cryostat section. These results indicate that: labeling myoblasts with FLMs can be used to trace the injected myoblasts in the muscle and to identify the muscle fibers that they formed; injected myoblasts remain near the injected site and do not migrate very far; most of the dystrophin-positive muscle fibers around the injected myoblasts result from fusion of the injected myoblasts; and the low percentage of dystrophin-positive muscle fibers is likely related to limited diffusion and lack of fusion of many injected myoblasts. (J Histochem Cytochem 41:1579-1582, 1993) " :
FLMs (fluorescent latex microspheres); mdx mouse; Myoblast transfer therapy; Dystrophin; Duchenne muscular dystrophy.
Materials and Methods
Myoblast Cultures. Primary myoblast cultures were established from fresh muscle biopsies of newborn normal mice (C57BLlOSnJ+ I+). Myogenic cells were released from minced fragments of the biopsy by serial enzyme treatments modified from Cossu et al. (8) . First, 1-hr digestion was done with 600 U/ml collagenase (Sigma; St Louis, MO) in Hank's balanced salt solution (HBSS) (Gibco; Grand Island, NY). This was followed by a 10-min incubation in HBSS containing 0.1% (wlv) trypsin (Gibco). Satellite cells were placed on 75-cm2 gelatin-coated culture flasks (Costar; Cambridge, MA) in proliferating medium (PM), i.e., 199 medium with 15% fetal bovine serum, 1% penicillin (final concentration 10,000 Ulml), and streptomycin (final concentration 10,000 Ulml) (7.9). All culture reagents were purchased from Gibco.
Labeling of Mononucleated Cells. FLMs (Luma Fluor; New City, NY)
were added to the mouse cultures at a dilution of 1:3000 in PM. Proliferating cells were incubated 12 hr at 37'C and then rinsed three times with HBSS. Incubation of mononucleated cells led to intemalization of the beads within the cytoplasm of 95% of the cells.
Cell Implantation. C57BL10 SnJ mdxlmdx mice were used as hosts. Fifty p1 of notexin (10 pg/ml) was first injected into the left tibialis anterior (TA) muscle of mdx mice to destroy muscle fibers and trigger regeneration (10.11). The following day normal myoblasts labeled with FLMs were transplanted. The myoblasts were detached with trypsin 0.1% and centrifuged. The mice were anesthetized with 0.1 ml of a solution containing 10 mglml of ketamine and 10 mglml of xylazine. An incision was made in the skin overlying the TA muscle of the left leg. Cell pellets were taken up into a glass micropipette with a 100-pm tip (Drummond Scientific; Broomall,
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PA) inserted at a shallow angle along the length of the muscle and withdrawn as the content was expelled. The TA muscle was injected at three different points with a total of 1 x lo6 cells. The skin was then closed with fine sutures. For immunosuppression, cyclosporin A at a dose 50 mglkg in soy oil was administered orally once a day starting the day of the myoblast injection.
Muscle Examination. Twenty-eight days after myoblast transplantation, mice were heart-perfused with saline under ketamine-xylazine anesthesia and the left TA muscles were dissected out and immersed in sucrose (30% in PBS) for 12 hr. The specimens were frozen in liquid nitrogen. Cryostat cross-sections (6 pm) of the muscles were thawed on gelatin-coated slides. Dystrophin was revealed by immunofluorescence and immunoperoxidase methods. For immunofluorescence the sections were incubated with 10% normal rabbit serum in PBS for 1 hr to block nonspecific binding sites. This was followed by a sheep polyclonal antibody against a fusion protein containing a 60 KD rod domain fragment of dystrophin as described by Hoffman et al. (12) . This antibody. R27. was provided by Genica Pharmaceuticals (Boston, MA). Sections were incubated for 1 hr with this antibody diluted 1:lOOO in PBS. Sections were rinsed five times (10 min each) with PBS and then reincubated with biotinylated rabbit anti-sheep IgG (Zymed;
San Francisco, CA) diluted 1:1000 in PBS. They were rinsed three times with PBS. The tissue was then incubated for 30 min with FIX-streptavidin (Zymed) and rinsed twice. For immunoperoxidase. the sections were first incubated with 1% H202 to quench endogenous peroxidase activity. After blocking nonspecific binding with 10% rabbit serum, the sections were incubated with the same primary and secondary antibodies by the same procedure as for the immunofluorescent method. The sections were then incubated for 45 min with avidin-coupled peroxidase (Vector; Burlingame. CA), followed by a 10-min rinse. Peroxidase activity was demonstrated by a 10-min incubation with diaminobenzidine (0.5 mglml) and H202 (0.015%).
Results
Intensely fluorescent cells labeled with FI.Ms were observed in different areas of the cross-section of the TA muscle. The fluorescent cells were localized in small regions and were not spread throughout the muscle (Figures la, Ib, and 2a ). Dystrophin was clearly revealed by the immunofluorescence (Figures 1b-Id) and immunoperoxidase (Figure 2 ) methods. The dystrophin-positive fibers were ob- served in clusters and were distributed near the myoblasts labeled with FLMs ( Figures Ib-ld and 2b-2d ). Except in these FLM-positive areas, there were only a few dysuophin-positive fibers which were probably due to back mutations (13). FLMs were present not only within the mononudear cells but also within some ofthe dystrophinpositive fibers (Figures Id, 2b, and 2c) . Almost all the muscle fibers that contained the FLMs were dystrophin positive. Although only a few dystrophin-positive fibers contained FLMs in a given cryostat section, examination of serial sections indicated that FLMs were present in most of the dystrophin-positive fibers.
Discussion
Implantation of myogenic cells into skeletal muscles of mdx mice has been conducted mainly to develop a therapy for human D M D (1-4). In these reports the replacement of the missing gene product, dystrophin, was verified quantitatively on immunoblots and histologically by immunostaining. Dystrophin is expressed on the surface of myotubes and muscle fibers (14-16) but not on myoblasts (17) ; therefore, the distribution of injected normal myoblasts cannot be followed with this marker. In this experiment the distribution of injected myoblasts was clearly demonstrated by intense fluorescence of FLMs. These findings agree with those of Alameddine et al. (6) , who demonstrated that the injected cells labeled with FLMs produced myotubes by fusion. However, these authors reported that the labeled myoblasts diffused in the necrotic section of the damaged muscles. In the present study, host muscles were full of muscle fibers and myoblasts. Injected myoblasts remained near the injection site and did not spread. On the basis of these results, it appears to be important to inject donor myoblasts at multiple sites so that dystrophin-positive muscle fibers can form throughout the host muscle.
In other reports, 3H-thymidine and bromodeoxyuridine (BrdU) were used to label proliferating cells. Such labels clearly demonstrated labeled nuclei (18) (19) (20) (21) (22) . However, with these nuclear labeling techniques the possibility of re-uptake by intact cells of label leaked from degenerated cells cannot be ruled out. Our previous in vitro study confirmed the uptake of FLMs by myoblasts and their transport into multinucleated myotubes by fusion (22). The E M S retained within the sarcoplasm of myoblasts and myotubes for several weeks had no cytotoxic effect. In the present in vivo study, FLMs taken up by myoblasts were transported to myotubes and muscle fibers and retained in the mononucleated cells or fused multinucleated cells for up to 28 days. The FLMs are very small (a few nanometers); the fluorescent granules in the myoblasts and muscle fibers appeared larger because the FLMs are accumulated inside some organelles (unpublished EM observations). The fact that FLMs were seen in some of the dystrophin-positive fibers indicates that FLMs do not inhibit cell fusion and dystrophin expression in vivo. Furthermore, because almost all the muscle fibers that contained FLMs were dystrophin positive, it can be assumed that re-uptake of FLMs by host cells was very rare. Therefore, labeling myoblasts with FLMs should be useful to identlfy the spread of injected myoblasts and to recognize dystrophin-positive fibers that are due to the fusion of injected myoblasts. In the present study, despite injection of notexin to destroy the muscle fibers before the injection of myoblasts, the percentage of dystrophin-positive fibers remained low. This may be due to the small dispersion of the injected myoblasts. It should also be noted that 1 month after their injection a large amount of myoblasts had not fused. It must also be considered that the dystrophin-positive muscle fibers containing FLMs may be the result of fusion of the donor myoblasts among themselves or with the host myoblasts. Unfortunately, it is not possible to distinguish between these possibilities with the present FLM labeling method.
